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Abstract
Two DNA vaccines were constructed encoding the ectodomain (domains I, II and III) of the DENV2 envelope protein (pE1D2)
or only its domain III (pE2D2), fused to the human tissue plasminogen activator signal peptide (t-PA). The expression and
secretion of recombinant proteins was confirmed in vitro in BHK cells transfected with the two plasmids, detected by
immunofluorescence or immunoprecipitation of metabolically labeled gene products, using polyclonal and monoclonal
antibodies against DENV2. Besides, results reveal that the ectodomain of the E protein can be efficiently expressed in vivo,i n
a mammalian system, without the prM protein that is hypothesized to act as a chaperonin during dengue infection. Balb/c
mice were immunized with the DNA vaccines and challenged with a lethal dose of DENV2. All pE1D2-vaccinated mice
survived challenge, while 45% of animals immunized with the pE2D2 died after infection. Furthermore, only 10% of pE1D2-
immunized mice presented some clinical signs of infection after challenge, whereas most of animals inoculated with the
pE2D2 showed effects of the disease with high morbidity degrees. Levels of neutralizing antibodies were significantly higher
in pE1D2-vaccinated mice than in pE2D2-immunized animals, also suggesting that the pE1D2 vaccine was more protective
than the pE2D2.
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Introduction
Dengue is a mosquito-borne viral disease spread widely in
tropical and subtropical regions in the world. It has been estimated
that over 2.5 billion people live in areas of infection risk [1,2]. In
Brazil, where climatic conditions favor proliferation of the
mosquito Aedes aegypti, the main vector of dengue viruses (DENV)
[3], the disease was reintroduced in 1986 and since then dengue
became a public health problem, with more than 7 million
reported cases until 2010 [4,5]. Virus infection can be asymptom-
atic or produce a broad spectrum of effects, including a mild
febrile illness, the dengue fever (DF), or severe disease forms, the
dengue hemorrhagic fever (DHF) and dengue shock syndrome
(DSS) [6].
The DENV are enveloped viruses, which belong to the family
Flaviviridae, genus Flavivirus, and consist of four antigenically
distinct serotypes (DENV1-4) [7]. The virus genome is composed
of a positive single-stranded RNA molecule, which codes a
polyprotein precursor that is processed to produce three structural
proteins, capsid (C), premembrane/membrane (prM/M) and
envelope (E), and seven nonstructural (NS) proteins, NS1,
NS2A, NS2B, NS3, NS4A, NS4B and NS5 [8]. The transmem-
brane E glycoprotein is the major component of virion surface and
it is associated with numerous biological activities, since it acts as a
binding protein, interacting with receptors present on host cell
surface, and mediate membrane fusion of the envelope virus and
host cell membrane [9,10]. It is organized in 90 homodimers that
become trimers at the fusion state [11]. Each monomer is
composed of domains I, II and III, in which the domain III is
responsible for the virus-cell interaction and trigger endocytosis of
the viral particle [11–13]. Consequently, this protein is the main
target for the induction of neutralizing antibodies, several of them
against epitopes present in domain III [14]. In fact, most vaccines
being developed against dengue virus are based on the induction
of immune responses directed to the E protein from all four
serotypes [15].
Several vaccine strategies have been proposed to control dengue
disease, including classical approaches, as inactivated or live
attenuated virus and subunit antigens, as well as new generation
vaccines, such as chimeric engineered viruses and DNA
immunization [10,16]. The DNA vaccine approach has the
advantage of in vivo antigen expression, leading to proper viral
protein folding with post-translation modifications, such as N-
linked glycosylation, which may be important for the induction of
protective immune responses [17,18]. DNA vaccines based on the
E protein from dengue virus have been reported by several
researchers [19–29], and most of them include prM and E gene
sequences, since the prM seems to act as a chaperonin that may be
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from its assembly site through the Golgi system [27,29]. However,
several of these DNA vaccines induced low levels of neutralizing
antibodies against dengue virus with consequently partial or short-
term protection in different animal models [19,21,23,27].
Moreover, most of these vaccines were constructed using the
natural virus sequences that act as signal peptides for the secretion
of these proteins, which may be not so efficient in the context of
DNA vaccination.
Therefore, in the present work, we constructed two DNA
vaccines encoding the ectodomain (domains I, II and III) of the
DENV2 envelope protein (pE1D2) or only its domain III (pE2D2),
fused to the human tissue plasminogen activator signal sequence (t-
PA). For the expression of the ectodomain, corresponding to the
80% N-terminal protein sequence, the hydrophobic stem-anchor
region of the envelop protein [30] was removed, in order to
increase the efficiency of expression and secretion of the
recombinant protein. On the hand, the t-PA sequence was used
because of its efficiency in mediating secretion of recombinant
proteins and antibody production in other DNA vaccines
constructed by our group against dengue virus [31–33]. Results
demonstrated that these plasmids were able to drive in vitro
expression and secretion of recombinant proteins in mammalian
cells. Both vaccines induced neutralizing antibody against DENV2
in Balb/c mice, although levels detected after immunization with
pE1D2 were significantly higher than with pE2D2. In addition, all
pE1D2-vaccinated mice survived challenge with a lethal dose of
DENV2, while several animals immunized with pE2D2 died after
virus infection or presented high morbidity rates.
Materials and Methods
Virus and Cells
The dengue 2 virus, strain New Guinea C (NGC DENV2), was
used for the isolation of sequences coding fragments of the E
protein and for challenge assays. The DENV2 44/2 [34] was used
for PRNT50 assays. Virus propagation was carried out in Vero
cells cultivated in Medium 199 with Earle salts (E199, Sigma,
USA) buffered with sodium bicarbonate and supplemented with
10% fetal bovine serum (FBS, Invitrogen, USA). For the
expression analysis of recombinant proteins in vitro, baby hamster
kidney cells (BHK-21) were propagated in Dulbecco’s Modified
Eagle Medium (DMEM, Invitrogen), supplemented with 5% FBS.
Construction of DNA vaccines
Two DNA vaccines were constructed encoding domains I, II
and III of the E protein or only the domain III, named pE1D2 and
pE2D2, respectively. These sequences were cloned in the pcTPA
plasmid [31], a modified pcDNA3 vector (Invitrogen) which
contains the human tissue plasminogen activator signal sequence
(t-PA). Sequences were amplified by PCR using as template a
previously constructed plasmid, pYFM/Nar, containing the full-
length prM-E genes of the NGC DENV2 [34]. Sense and
antisense primers, 59GGGGGATATCATGCGTTGCATAGGAA-
TATC39 and 59GGGGTCTAGATTAGATAGAACTTCCTTTC39,
which anneals on the NGC DENV2 sequence (GenBank
M29095), between nucleotides 937 to 956 and 2115 to 2130,
respectively, were used for amplification of the E1D2 sequence,
which corresponds to amino acids 1–398 of the E protein [35]. For
amplification of the E2D2 sequence, encoding domain III of the E
protein (amino acids 296–398), the sense primer 59GGGGGA-
TATCGGAATGTCATACTCTATG 39, which anneals at the
nucleotide 1822 to 1839 in the NGC DENV2 sequence, was used
together with the antisense primer described above. Sense and
antisense primers contained EcoRV and XbaI restriction sites,
respectively. The PCR products were electrophoresed on a 1%
agarose gel, recovered with glass beads, geneclean (Stratagene,
USA), restricted with EcoRV and XbaI and ligated to the pcTPA
previously digested with the same enzymes. All recombinant
plasmids were screened by restriction mapping and confirmed by
sequencing (ABI Prism dye terminator, Applied Biosystems, USA,
performed by the Genomic Platform DNA Sequencing, PDTIS-
Fiocruz). Recombinant plasmids were isolated from transformed
Escherichia coli, DH5-a strain, and purified by Qiagen Plasmid Giga
Kit (Qiagen, Germany), following manufacturer’s instruction.
DNA concentrations were determined by measuring optical
density at 260 nm and integrity of plasmids was checked by
agarose gel electrophoresis. Plasmids were suspended in sterile
water and stored at 220uC until use.
Cell transfection and Immunofluorescence assay
BHK cells were transiently transfected with the DNA vaccines
pE1D2 and pE2D2 or the control plasmid pcTPA, as previously
described [33]. Briefly, 2610
4 cells/well were plated in chamber
slides (Nunc, Denmark) with Optimen medium (Invitrogen) and
transfected with 0.2 mg of each DNA using lipofectamine
(Invitrogen) under conditions suggested by the manufacturer. Cell
monolayers were then maintained over night at 37uC with 5%
CO2. In the following day, cells were washed in 0.1 M phosphate
buffer pH 7.4, fixed in 4% paraformaldehyde for 10 min,
permeabilized with 0.6% saponin for 10 min and blocked with
1% bovine serum albumin (BSA) and 0.2% saponin for 15 min.
Cells were then incubated for 1 h at 37uC with DENV2
hyperimmune mouse ascitic fluid (ATCC, USA), diluted 1:1500,
or the monoclonal anti-DENV2 3H5 (ATCC), diluted 1:500.
Slides were then washed tree times and incubated for 1 h at 37uC
with fluorescein-conjugated goat anti-mouse IgG (Southern
Biotechnology, USA), diluted 1:100, washed again and mounted
with Vectashield medium (Vector Laboratories Inc., USA). Cells
were visualized in a fluorescence microscope (Nikon Eclipse E600).
Metabolic labeling and imunoprecipitation
For protein analysis, 5610
5 BHK-21 cells were transfected with
2 mg of each DNA as described above. In the following day, cells
were metabolically labeled using [
35S] methionine (80 mCi/mL)
for 1:30 h, in methionine-deficient RPMI 1640 medium (Sigma)
without FBS. Culture supernatants were then immunoprecipitated
with DENV2 hyperimmune mouse ascitic fluid, as previously
described [36]. Protein samples were analyzed by 12% sodium
dodecyl sulfate-polyacrylamide gel (SDS-PAGE) electrophoresis.
Gel was dried and exposed to Kodak X Omat film for
visualization of the labeled proteins.
Immunization of Balb/c mice
Experiments with mice were conducted in compliance with
ethical principles in animal experimentation stated in the Brazilian
College of Animal Experimentation and approved by the
Institute’s Animal Use Ethical Committee (approval ID: L-067/
08). Balb/c mice, 4 to 6 weeks old, were immunized by the
intramuscular (i.m.) route with 100 mg of recombinant plasmids
(50 mg in each tibialis posterior muscles), prepared in 100 mLo f
phosphate buffer saline (PBS) and using 27-gauge needles. Each
mouse group (n=10) received two doses of the DNA vaccine
(pE1D2 or pE2D2) or the pcTPA vector, given 2 weeks apart.
Two independent experiments were performed for each mouse
group. Animals were bled by retro-orbital puncture, before
inoculation (pre-immune sera), two weeks after the second
immunization and 21 days after challenge, when all survived
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at -70uC until use.
Plaque reduction neutralization test (PRNT50)
Plaque reduction neutralization tests (PRNT) were carried out
on Vero cells, in 96-well plates, as previously described [37].
Briefly, serum samples were serially diluted (from 1:5 to 1:640) in
50 mL of E199 medium followed by the addition of 50 mLo f
DENV2, corresponding to approximately 30 PFU, and incubated
at 37uC for 1 h. Suspension of Vero cells were then added
(2,5610
4 cells/well) and plates were incubated at 37uC for 3 h.
After this period, media were discarded, cells were overlaid with
100 mL of E199 medium with 3% carboxymethylcellulose and
plates were incubated for 7 days at 37uCi n5 %C O 2. Cells were
then fixed with 10% formalin, stained with crystal violet and
plaques were counted. Neutralizing antibody titers were expressed
by 50% of plaque reduction (PRNT50).
Mouse challenge with DENV2
Two weeks after the second DNA dose, mice were challenged
with a mouse brain adapted sample of NGC DENV2. Animals
were anesthetized with a mixture of ketamine-xylazine [38] and
intracerebrally (i.c.) inoculated with 30 mL of 4.32 log10 PFU of
DENV2, which corresponds to 3.8 LD50, diluted in E199 medium
supplemented with 5% FCS. Immediately after challenge
procedure, the inoculum was back-titered in Vero cells as
described previously [34]. One group of non-immunized animals,
challenged with DENV2, was also included as negative control.
Animals were monitored for 21 days for mortality and morbidity,
mainly the appearance of leg paralysis, alterations in spinal
column and deaths. The evaluation of different morbidity degrees
in each animal group was performed using a scale ranging from 0
to 3 (0=none, 1= mild paralyses in one hind leg or alteration of
the spinal column with a small hump, 2= severe paralyses in one
hind leg and alteration of the spinal column with a small hump or
severe paralyses in both hind legs, 3= two severe hind leg
paralyses and deformed spinal column or death). Two indepen-
dent challenge tests were performed in the same experimental
conditions.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
software (La Jolla, USA), version 5.02. For the analysis of survival
and morbidity rates, statistical significances were evaluated by chi-
square test, while differences in the degree of morbidity and
PRNT50 titers were analyzed by Mann-Whitney test. Values were
considered significant at p,0.05.
Results
Construction of the recombinant plasmids pE1D2 and
pE2D2
Two DNA vaccines (pE1D2 and pE2D2) were constructed
encoding fragment sequences from the NGC DENV2 envelope
protein. The plasmid pE1D2 contains the truncated sequence that
encodes the first 398 amino acids, corresponding to domains I, II
and III of the E protein, without the hydrophobic stem-anchor
region, while the pE2D2 plasmid encodes only its domain III
(from amino acid 296 to 398) (Fig. 1). Both fragments were cloned
in frame with the t-PA signal sequence, which was used to target
recombinant proteins into endoplasmic reticulum and its secretion
to extracellular space.
Analysis of the in vitro expression of recombinant
proteins
The in vitro expression of recombinant proteins was evaluated in
BHK-21 cells transiently transfected with the plasmids pE1D2 and
pE2D2. Immunofluorescence assays revealed that cells transfected
with these plasmids showed positive reaction with a hyperimmune
ascitic fluid that recognized several epitopes of the DENV2 E
protein during infection (Figs. 2A and 2B). The two recombinant
proteins were also detected by the monoclonal 3H5 antibody,
which is specific for a neutralizing epitope present on the domain
III of the DENV2 envelope protein (Figs. 2D and 2E). As
expected, no reaction was detected in control cells transfected with
the pcTPA plasmid, using either the polyclonal or the monoclonal
antibodies against DENV2 (Figs. 2C and 2F).
The recombinant proteins were also observed in culture
supernatants of transfected cells metabolic labeled, which were
immunopreciptated with DENV2 hyperimmune ascitic fluid, thus
revealing their secretion with expected molecular weights
(approximately 44 KDa and 12 KDa for pE1D2 and pE2D2,
respectively) (Fig. 3).
Protective efficacy of the DNA vaccines in Balb/c mice
Balb/c mice were immunized by the i.m. route with one of the
two different DNA vaccines and challenged by i.c. inoculation
Figure 1. Schematic representation of the DENV2 envelope protein sequence. The protein is composed by the three domains (I, II and III)
and the steam-anchor region (adapted from Modis et al. [12]). The sequence coding 80% of the N-terminal E protein, which contains domains I, II and
III, was used for engineering the pE1D2 plasmid, while the pE2D2 plasmid encoded only the domain III sequence. Numbers indicated in the figure
highlight amino acids corresponding the beginning and end positions at the primary protein sequence that compose each domain.
doi:10.1371/journal.pone.0020528.g001
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control groups, non-immunized or pcTPA-inoculated animals
were also challenged with DENV2. Animals were monitored the
following 21 days after challenge for the development of leg
paralysis, alterations in spinal column and death. Two indepen-
dent challenge experiments were performed for each vaccine at
the same conditions and data are summarized in figures 4 and 5.
All animals vaccinated with the pE1D2 plasmid survived
challenge while 45% of mice immunized with the plasmid
pE2D2 died after virus inoculation, and such differences were
statistically significant (p=0.0027) (Fig. 4). On the other hand,
only 15% and 10% of animals in control groups (non-immunized
or inoculated with the control vector pcTPA, respectively) survived
after virus challenge (Fig. 4). All vaccinated animal groups, pE1D2
or pE2D2, presented significant differences in survival rates when
compared to control groups (p,0.0001). Furthermore, control
animals showed severe clinical signs of infection, starting at the 8
th
day after challenge, and reached maximal levels of morbidity
(100% and 90% in non-immunized or pcTPA-inoculated mice,
respectively) in the following days (Fig. 5A). In contrast, only 10%
of mice immunized with the pE1D2 vaccine presented clinical
signs of the disease after the 19
th day post infection (Fig. 5A) with
less severe morbidity degrees (Fig. 5B). Nevertheless, animals
inoculated with pE2D2 presented clinical signs of infection from
days 7 through 12 post challenge (65% of morbidity) (Fig. 5A). In
this group, 45% of mice presented the highest severity of
neurological signs (degree 3) and another 20% showed morbidity
ranging from degree 1 to 2 (Fig. 5B). The differences between
pE1D2- and pE2D2-vaccinated mouse groups were statistically
significant, concerning either morbidity rates (p,0.0001) or the
severity of the disease (p=0.0002). However, both groups showed
Figure 2. Analysis of the expression in vitro of recombinant proteins. BHK cells were transfected with plasmids pE1D2 (A, D), pE2D2 (B, E) and
pcTPA (C, F). Cells were permeabilized, fixed and treated with DENV2 hiperimmune mouse ascitic fluid (A–C) or the monoclonal DENV2 3H5 antibody
(D–F), followed by incubation with anti-mouse fluorescein-conjugated goat IgG. Magnification 1000x (A, B, D, E) and 400x (C, F).
doi:10.1371/journal.pone.0020528.g002
Figure 3. Electrophoretic analysis of recombinant proteins
secreted by transfected BHK cells. Cells were metabolically labeled
with [
35S] methionine and culture supernatants were immunoprecip-
itated with DENV2 hiperimmune mouse ascitic fluid. Culture superna-
tants of cells transfected with pE1D2 (lane 1), pE2D2 (lane 2) or pcTPA
(lane 3). Arrows indicate recombinant proteins.
doi:10.1371/journal.pone.0020528.g003
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control mice inoculated with the vector pcTPA (p,0.0001 and
p=0.0051, for pE1D2- and pE2D2-vaccinated animals, respec-
tively).
Neutralizing antibodies elicited by the DNA vaccines
The humoral immune response generated after immunization
of Balb/c mice with the two DNA vaccines was analyzed by the
presence of neutralizing antibodies. Serum samples from all
vaccinated mice were collected two weeks after the second DNA
dose, as well as from animals that survived challenge, obtained 21
days post infection, and titrated for neutralizing antibodies
(PRNT50) using a different DENV2 isolate. Mice immunized with
the pE1D2 vaccine presented significantly higher PRNT50 titers
when compared to animals inoculated with the pE2D2
(p=0.0029) (Fig. 6). Furthermore, the DENV2 virus challenge
induced a remarkable increase in the levels of neutralizing
antibodies in pE1D2-vaccinated mice, in which most of them
(95%) reached the maximal neutralization titer used in this assay
(1$640). In contrast, pE2D2-vaccinated animals that survived
virus infection (11 mice) presented a broad range of neutralizing
antibody levels after challenge and only six of them (55%) showed
maximum PRNT titers (Fig. 6).
As expected, pre-immune serum samples and sera collected
from pcTPA-inoculated mice did not present detectable neutral-
izing antibody titers against DENV2 (data not shown).
Discussion
In the present report we describe the construction of two DNA
plasmids encoding the ectodomain (domains I, II and III) of the
DENV2 envelope protein (pE1D2) or its domain III (pE2D2),
fused to the t-PA signal peptide, in order to study the potential of
such vaccines to induce antibody responses and protection in mice.
The E protein was chosen since it is the major protein present on
the surface of virus particle and it contains several epitopes that
elicit neutralizing antibodies against DENV [39].
The expression of recombinant proteins was evaluated in vitro by
the transfection of BHK cells with the two plasmids and detected
by immunofluorescence assays. Results indicate that these DNA
vaccines drove correct expression of such proteins in mammalian
cells, since they were recognized by a polyclonal anti-dengue
ascitic fluid that contains antibodies reacting to epitopes present on
the DENV2 envelope protein during virus infection in different
cells [27,40,41]. Furthermore, the proteins expressed by transfect-
ed cells were also recognized by the monoclonal antibody 3H5
[42], which is specific to a neutralizing epitope present on the
domain III of the DENV2 envelope protein [43], thus revealing
Figure 4. Percentage of survival of Balb/c mice immunized with
pE1D2 and pE2D2 and challenged with DENV2. Mice were i.m.
immunized with two DNA doses and challenged 4 weeks after the first
plasmid inoculation. Non-immunized and pcTPA-injected mice followed
the same virus infection procedure. Mice were daily monitored and
deaths were recorded. Differences between pE1D2- and pE2D2-
vaccinated animals were statistical significant (p=0.0027), as well as
between these groups and control animals (p,0.0001). Data represent
compilation of two independent experiments, with groups of 10
animals in each test (n=20).
doi:10.1371/journal.pone.0020528.g004
Figure 5. The morbidity in vaccinated mice after DENV2 challenge. The percentage (A) and degree (B) of morbidity of Balb/c mice
immunized with pE1D2, pE2D2 and controls groups (non-immunized and pcTPA-inoculated animals) were analyzed after i.c. challenge with DENV2.
Clinical signs of infection, mainly hind leg paralysis, alterations in spinal column and deaths, were monitored during 21 days post challenge (A).
Differences in morbidity rates between pE1D2- and pE2D2-vaccinated mice were statistical significant (p,0.0001), as well as between pE1D2 and
control animals (p,0.0001). The semi-quantitative analysis of morbidity degrees after virus challenge (B) were performed using a subjective scale
ranging from 0 to 3 (0=none, 1= mild paralyses in one hind leg or alteration of the spinal column with a small hump, 2= one severe hind leg
paralyses and alteration of the spinal column with a small hump or two severe hind leg paralyses, 3= two severe hind leg paralyses and deformed
spinal column or death). Asterisks indicate statistically significant differences between vaccinated animals and mice inoculated with the control vector
pcTPA (* p=0.0051; ** p=0.0002; *** p,0.0001). Data represent compilation of two independent experiments, with groups of 10 animals in each test
(n=20).
doi:10.1371/journal.pone.0020528.g005
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proteins expressed by the two DNA vaccines. In the present study,
plasmids were constructed with the t-PA signal sequence, which
has already been used in other DNA vaccines and successfully
mediated secretion of recombinant antigens with the induction of
robust antibody responses [31–33]. Likewise, we observed
secretion of the recombinant proteins mediated by both plasmids,
pE1D2 and pE2D2.
Expression and immunogenicity of these proteins was then
confirmed in vivo, by vaccination of Balb/c mice with the two
different DNA vaccines, in which both plasmids were able to elicit
neutralizing antibodies against DENV2. However, animals
vaccinated with the pE1D2 plasmid presented significantly higher
titers of neutralizing antibodies, when compared to pE2D2-
inoculated mice. Although domain III in this case was immuno-
genic, since pE2D2-inoculated mice showed detectable levels of
neutralizing antibodies, it seems not to be sufficient for the
induction of an immune response with a magnitude similar to
what was observed when we used larger segment of the E protein.
Actually, the pE1D2 plasmid contains the sequence coding for the
ectodomain of the E protein, which appears to be important for
the generation of high levels of neutralizing antibodies, at least in
the context of DNA vaccines. In fact, domains I and II also
contain epitopes that generate antibodies which interfere with
virus infection in cell culture [44], and therefore they could
contribute for the highest neutralizing antibody levels detected in
pE1D2-immunized mice. Moreover, Wahala and coworkers
recently characterized the binding specificity and functional
properties of human DENV immune sera and demonstrated that
antibodies against domain III do not play the major role in DENV
neutralization. Authors suggest, therefore, that other epitopes
present on other locations in the E protein are primarily
responsible for virus neutralization [45].
The protocol for mice immunization with DNA vaccine using
the intramuscular route is a well established procedure that
efficiently elicit robust immune responses in these animals, as
shown by several authors [29,31–33,46], including our group with
another plasmid encoding the DENV2 NS1 gene, in which the
construction was similar to the pE1D2 and pE2D2 [31–33]. In
general, the use of two doses of these DNA vaccines was already
sufficient to induce desirable immune responses in mice [27,31]. In
the case of a DNA vaccine encoding the DENV2 NS1 gene, also
fused to the t-PA signal sequence, animals inoculated with three
plasmid doses presented only a transient increase in antibody
levels, revealing a significant reduction in the following weeks,
when they showed titers similar to those observed in mice
immunized with only two DNA doses [31]. Moreover, it is always
advantageous the use of a vaccine protocol with lower number of
doses, especially in the case of immunizations against dengue in
endemic regions, minimizing the risk of developing severe cases of
the disease between vaccination intervals, in which a robust
protective immune response is not completely achieved yet [47].
On the other hand, the ectodomain of the dengue envelope
protein expressed in pE1D2 vaccinated mice, without the stem-
anchor region, showed to be efficient for the induction of a
protective immune response in mice after two DNA doses. The
rationale for removing such region, which is localized on the C-
terminal end of the protein, is because it is a highly hydrophobic
amino acid sequence that may interfere with the expression and/
or secretion of the protein, especially in heterologous systems.
DNA vaccines based on truncated dengue envelope proteins were
already developed for the induction of immune responses and
protection against this virus [19,22,24]. All of these constructions
used the dengue natural signal sequence present on the C-terminal
end of the prM protein and none of them were fully protective,
probably because of the lack of an efficient signal peptide for the
context of DNA vaccines. On the other hand, some authors have
used the t-PA sequence fused to the truncated E gene of Japanese
encephalitis virus and they observed that such DNA vaccine
conferred higher level of protection when compared to other
tested plasmids [48].
Most of reported DNA vaccines against dengue and other
flaviviruses are based on the full length of the prM and E genes
[23,27,49–53], since it is believed that coexpression of both
proteins is important for the correct folding of the E protein [8].
However, these proteins contain highly hydrophobic regions that
may interfere with their expression and/or secretion [8]. In fact,
some studies with DNA vaccines encoding prM/E sequences
showed the induction of low titers of neutralizing antibodies and
partial protection, even after several DNA doses [23,46]. To
overcome this difficulty, researchers employed other strategies
such as the use of lysosomal targeting, immune stimulatory and/or
cytokine sequences, prime/booster immunization regimen, etc
[20,25,26,28,54]. Besides all such difficulty, recently Dejnirattisai
et al. [55] showed that human monoclonal antibodies against the
prM protein not only display limited virus neutralization capacity
but may also enhance infection. Actually, it seems that the
combination of partial cleavage of the prM, together with
substantial cross-reaction between serotypes makes the anti-prM
response particularly susceptible to enhancement of virus infection
[55]. Therefore, the use of the envelope protein without the prM,
as we did in the present work, may be more appropriate for the
development of a vaccine against dengue virus, avoiding the risk of
the increase of enhancement activities.
Immunization with the DNA plasmid encoding only the domain
III (pE2D2), in its turn, induced low levels of neutralizing
antibodies and incomplete protection against a lethal dose of
DENV2. In contrast, other reports, using DNA vaccines encoding
the domains III of the envelope protein from the four dengue
serotypes, demonstrated different results [56,57]. Ramanathan
Figure 6. Plaque reduction neutralization test. The neutralizing
antibody titrations (PRNT50) against DENV2 was evaluated in serum
samples collected from pE1D2- and pE2D2-vaccinated mice (n=20),
before and after virus challenge. Individual samples were serially diluted
from 1:5 to 1:640 and PRNT50 were performed in 96-well plates as
described in material and methods. Asterisks indicate differences that
are statistically significant between pE1D2- and pE2D2-immunized
animals (*, p=0.0029) or between vaccinated mice before and after
virus challenge (***, p,0.0001).
doi:10.1371/journal.pone.0020528.g006
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responses against all virus serotypes, with the production of
neutralizing antibodies. However, in this study neutralizing
antibody levels was not evaluated by PRNT50 assays, as performed
in our work, and mice were not challenged with DENV in order to
evaluate protection [56]. On the other hand, Mota et al. [57] using
a combination of four DNA vaccines with the domain III of each
virus serotype, have revealed protection induced by such vaccines.
However, authors used indirect challenge models, by analyzing
suckling mice inoculated with dengue viruses that were pre-
incubated with immunized mouse serum samples, which may not
reproduce what happens with adult animals [57]. In addition, the
humoral immune response induced by such vaccines was of low
magnitude, evaluated by ELISA, and the presence of neutralizing
antibodies was not quantified [57].
The protective efficacy of our DNA vaccines was investigated by
challenge tests with a lethal dose of a mouse brain adapted
DENV2 isolate. Although such mouse challenge model, with i.c.
virus inoculation, is quite distinct to what occur with humans, we
choose it because it is the most widely used model for vaccines tests
against dengue virus [19,20,22,34,58,59] and, therefore, we could
compare our results with those described in these studies.
In accordance to the levels of neutralizing antibodies observed
in pE1D2-immunized mice, this animal group also showed high
protective rates. Indeed, all Balb/c mice vaccinated with such
plasmid survived challenge and only two animals (10%) presented
some minor evidence of infection. On the other hand, protection
conferred by the pE2D2 plasmid was only partial, since most of
animals (65%) immunized with such vaccine showed clinical signs
of infection after virus challenge and 45% of mice died in the
following days. The pre-existing immunity in pE1D2-vaccinated
mice is probably the basis for the observed protection, given the
significant increase of antibody titers after virus challenge, which
indicates the activation of immunological memory with rapid and
strong secondary immune response, may have also contributed for
such protection. However, we could not establish a direct
correlation between morbidity degrees observed after challenge
in animals immunized with the pE2D2 and their PRNT titers.
Previous reports have shown that immunization with monoclonal
antibodies against dengue virus with strong neutralizing activities
in vitro induce different degrees of protection in vivo [60].
These studies suggested that the levels of neutralizing antibodies
are not the only parameter to be investigated, since the
stoichiometry of antibody binding may also be important for
protection [60]. On the other hand, passive immunization of mice
inoculated with sera collected from pE1D2-vaccinated animals
revealed partial protection after virus challenge (34%), while the
mean time to death was protracted (data not shown). Thus, our
results suggest that, although neutralizing antibodies are important
for protection against dengue virus, other branches of the immune
response may also play a role in such protection. In fact, some
reports have shown that cellular immune responses, including the
activation of TCD4+ and TCD8+ cells, seem to be involved in
protection against DENV [61–63].
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